Stock 719 SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shandong Xinhua Pharmaceutical Company Limited

Equities

719

CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
5.45 HKD +0.74% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited +3.81% -5.71%
Apr. 25 Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 11 Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,992 3,875 4,585 5,578 15,668 10,813
Enterprise Value (EV) 1 3,645 4,714 5,374 6,446 15,893 11,254
P/E ratio 7.99 x 7.11 x 5.75 x 6.82 x 11.8 x 7.3 x
Yield 3.13% 3.52% 5.02% 3.96% 2.78% 4.76%
Capitalization / Revenue 0.57 x 0.69 x 0.76 x 0.85 x 2.09 x 1.33 x
EV / Revenue 0.7 x 0.84 x 0.89 x 0.98 x 2.12 x 1.39 x
EV / EBITDA 5.56 x 6.43 x 6.39 x 7.69 x 16.7 x 11 x
EV / FCF 45.1 x 34.8 x 10.8 x 25.1 x 20.4 x 225 x
FCF Yield 2.22% 2.87% 9.23% 3.98% 4.9% 0.44%
Price to Book 0.74 x 0.72 x 0.58 x 0.69 x 1.17 x 0.78 x
Nbr of stocks (in thousands) 621,859 621,859 621,859 627,367 669,627 674,683
Reference price 2 3.196 3.414 2.988 3.789 7.198 5.253
Announcement Date 3/22/19 3/20/20 3/30/21 3/30/22 3/26/23 3/28/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5,208 5,606 6,006 6,560 7,503 8,101
EBITDA 1 655.8 732.9 841.5 838.4 950.2 1,023
EBIT 1 354.2 390.3 458.8 403.7 465.9 512.2
Operating Margin 6.8% 6.96% 7.64% 6.15% 6.21% 6.32%
Earnings before Tax (EBT) 1 325.1 381.4 411.6 421.2 471.8 532.7
Net income 1 250.8 300 324.9 348.5 411.2 496.5
Net margin 4.82% 5.35% 5.41% 5.31% 5.48% 6.13%
EPS 2 0.4000 0.4800 0.5200 0.5558 0.6100 0.7200
Free Cash Flow 1 80.81 135.3 496.1 256.4 779.3 50.07
FCF margin 1.55% 2.41% 8.26% 3.91% 10.39% 0.62%
FCF Conversion (EBITDA) 12.32% 18.47% 58.95% 30.59% 82.02% 4.89%
FCF Conversion (Net income) 32.22% 45.12% 152.71% 73.57% 189.53% 10.08%
Dividend per Share 2 0.1000 0.1200 0.1500 0.1500 0.2000 0.2500
Announcement Date 3/22/19 3/20/20 3/30/21 3/30/22 3/26/23 3/28/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 653 839 789 868 225 440
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.9953 x 1.145 x 0.9381 x 1.035 x 0.2369 x 0.4303 x
Free Cash Flow 1 80.8 135 496 256 779 50.1
ROE (net income / shareholders' equity) 10.2% 10.9% 10.7% 10.3% 10.7% 11.1%
ROA (Net income/ Total Assets) 3.96% 3.94% 4.24% 3.5% 3.73% 3.87%
Assets 1 6,340 7,616 7,664 9,965 11,013 12,836
Book Value Per Share 2 4.320 4.770 5.180 5.530 6.160 6.750
Cash Flow per Share 2 1.250 1.110 1.380 1.190 1.730 1.360
Capex 1 386 367 280 249 245 325
Capex / Sales 7.41% 6.54% 4.67% 3.8% 3.26% 4.01%
Announcement Date 3/22/19 3/20/20 3/30/21 3/30/22 3/26/23 3/28/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED Stock Shandong Xinhua Pharmaceutical Company Limited
-5.71% 1.19B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 719 Stock
  4. Financials Shandong Xinhua Pharmaceutical Company Limited